Patents Represented by Attorney Roberta L. Robins
  • Patent number: 8216590
    Abstract: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: July 10, 2012
    Assignee: Novartis AG
    Inventors: Michael Houghton, Yin-Ling Lin, Angelica Medina-Selby, Doris Coit
  • Patent number: 7198923
    Abstract: The invention relates to a method for the isolation of hepatitis C virus. The method comprises the separation of particles termed exosomes from the blood plasma of an individual infected with hepatitis C virus (HCV) and the extraction or RNA from these exosome particles.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: April 3, 2007
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sergio Abrignani, Piero Pileri
  • Patent number: 7183107
    Abstract: This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV sub-genomic replicons. The invention also provides methods of using the cells of the invention to screen for compounds that modulate viral RNA replication, including HCV RNA replication.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: February 27, 2007
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mark Selby, Hui-Hua Lu
  • Patent number: 7179457
    Abstract: The invention provides a nodavirus RNA1 molecule modified to include a heterologous insertion which is downstream of its replicase ORF and, preferably, its B2 ORF. The insertion preferably comprises one or more protein-coding regions. The modified RNA1 may be packaged in a VLP, such as a papillomavirus VLP. The small size of nodavirus RNA1 makes it ideal for HPV packaging.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: February 20, 2007
    Assignee: Chiron S.r.l.
    Inventors: Giuliano Bensi, Alessio Zippo
  • Patent number: 7169392
    Abstract: The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: January 30, 2007
    Assignee: Chiron Srl
    Inventor: Robert Seid
  • Patent number: 7135185
    Abstract: Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a pharmaceutically acceptable carrier, such as a diphtheria toxoid.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: November 14, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Amy J. Weiner, Michael Houghton
  • Patent number: 7105303
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 12, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 7097987
    Abstract: The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: August 29, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sergio Abrignani, Guido Grandi
  • Patent number: 7098303
    Abstract: Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a bacterial toxoid, such as a diphtheria toxoid.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: August 29, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Amy J. Weiner, Michael Houghton
  • Patent number: 7084119
    Abstract: The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues; C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163 N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23 by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23 and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: August 1, 2006
    Assignee: Chiron Corporation
    Inventors: Denis J. Gospodarowicz, Frank R. Masiarz
  • Patent number: 7067485
    Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: June 27, 2006
    Assignee: Chiron Corporation
    Inventors: Bret A. Shirley, Maninder S. Hora
  • Patent number: 7063949
    Abstract: Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: June 20, 2006
    Assignees: Chiron Corporation, Children's Hospital Medical Center of Northern California
    Inventors: Dan M. Granoff, Gregory R. Moe
  • Patent number: 7056658
    Abstract: Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x?(B)y?C2 which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 6, 2006
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Patent number: 7048924
    Abstract: Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: May 23, 2006
    Assignee: Chiron Corporation
    Inventor: David Sahner
  • Patent number: 7033805
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: April 25, 2006
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Patent number: 7026130
    Abstract: A 24kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24kd protein, are disclosed. Processes for production and purification of the 24kd protein, and functionally equivalent variants or fragments thereof, are also disclosed, as are methods for using the protein to screen for chemical compounds that bind HCV.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 11, 2006
    Assignee: Chiron Corporation
    Inventor: Sergio Abrignani
  • Patent number: 6986892
    Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupt the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: January 17, 2006
    Assignee: Chiron Corporation
    Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
  • Patent number: 6939849
    Abstract: DNA encoding two forms of PDGF A-chain polypeptide, the construction of expression vectors for expressing such DNA in yeast and mammalian cells, and the expression of such DNA in yeast and mammalian cells to produce active PDGF A-chain homodimer and active PDGF A-chain/B-chain heterodimer are disclosed.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 6, 2005
    Assignee: Chiron Corporation
    Inventors: Carl-Henrik Heldin, Christer Betsholtz, Bengt Westermark, Timothy J. Knott, James Scott, Graeme I. Bell
  • Patent number: 6936442
    Abstract: Human parvovirus B19 primers and probes derived from conserved regions of the parvovirus B19 genome are disclosed. Also disclosed are nucleic acid-based assays using the primers and probes.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: August 30, 2005
    Assignee: Chiron Corporation
    Inventors: Sergio Pichuantes, Venkatakrishna Shyamala
  • Patent number: 6914131
    Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: July 5, 2005
    Assignee: Chiron S.r.l.
    Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi